15 Best Growth Stocks to Invest in for the Next 5 Years

12. Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Upside potential as of June 24, 2025: 101.36%

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced the approval of an amendment to the 2023 Stock Incentive Plan to make room for future growth. According to the amendment, which was authorized during the company’s Annual Meeting of Stockholders on June 10, 2025, the shares to be issued will increase by 18,900,000.

During the meeting, the two Class II directors, John P. Butler and Myles Wolf, M.D., M.M.Sc., were also elected until the annual meeting of stockholders in 2028. While John P. Butler received 130,424,556 votes, the latter secured 119,938,011 votes. The leadership changes follow the impressive one-year return of over 300% delivered by Akebia Therapeutics, Inc. (NASDAQ:AKBA), reinforcing its strong position in the market.

In addition to the stock incentive amendment plan and executive appointments, stockholders extended advisory approval to compensate the company’s named executive officers. With 178,590,132 votes cast in favor, Ernst & Young LLP was also selected as the giant’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a Massachusetts-headquartered biopharmaceutical company that develops and commercializes therapies for people living with kidney diseases. Founded in 2007, the company offers Vafseo (vadadustat) and Auryxia, alongside the ongoing development of AKB-9090 and AKB-10108. Through a collaboration with Mitsubishi Tanabe Pharma Corporation, the company is dedicated to improving the lives of many.